Hill AM - Search Results

1

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.

Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene CM, Hill AM, Meintjes G, Maartens G. Griesel R, et al. Among authors: hill am. Lancet HIV. 2023 Jul;10(7):e433-e441. doi: 10.1016/S2352-3018(23)00081-4. Epub 2023 May 22. Lancet HIV. 2023. PMID: 37230101 Free PMC article. Clinical Trial.

2

The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.

Hill AM, Nath S, Simmons B. Hill AM, et al. J Virus Erad. 2017 Jul 1;3(3):117-123. J Virus Erad. 2017. PMID: 28758018 Free PMC article.

3

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.

Zhao Y, Griesel R, Omar Z, Simmons B, Hill A, van Zyl G, Keene C, Maartens G, Meintjes G. Zhao Y, et al. Clin Infect Dis. 2023 May 24;76(10):1832-1840. doi: 10.1093/cid/ciad023. Clin Infect Dis. 2023. PMID: 36645792 Free PMC article. Clinical Trial.

4

Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.

Keene CM, Cassidy T, Zhao Y, Griesel R, Jackson A, Sayed K, Omar Z, Hill A, Ngwenya O, Van Zyl G, Flowers T, Goemaere E, Maartens G, Meintjes G. Keene CM, et al. J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):422-429. doi: 10.1097/QAI.0000000000003157. J Acquir Immune Defic Syndr. 2023. PMID: 36706364 Free PMC article.

5

Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.

Sokhela S, Venter WDF, Bosch B, Woods J, McCann K, Akpomiemie G, Chandiwana N, Mashabane N, Tembo A, Simmons B, Lalla-Edward S, Siedner MJ, Sinxadi P, Hermans L, Fairlie L, Vos A, Abrams E, Manne-Goehler JM, Moorhouse M, Clayden P, Norris S, Qavi A, Chersich M, Masenya M, Arulappan N, Hill A. Sokhela S, et al. Open Forum Infect Dis. 2024 Jan 24;11(3):ofae007. doi: 10.1093/ofid/ofae007. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38529213 Free PMC article.

6

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.

Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Lancet Infect Dis. 2024 May 28:S1473-3099(24)00289-5. doi: 10.1016/S1473-3099(24)00289-5. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38821073

7

The unexpected success of NRTIs in second-line treatment.

Hill AM, Venter F. Hill AM, et al. Lancet Infect Dis. 2018 Jan;18(1):3-5. doi: 10.1016/S1473-3099(17)30631-X. Epub 2017 Nov 3. Lancet Infect Dis. 2018. PMID: 29108798 Free article. No abstract available.

8

International disparities in diagnosis and treatment access for cystic fibrosis.

Guo J, King I, Hill A. Guo J, et al. Pediatr Pulmonol. 2024 Jun;59(6):1622-1630. doi: 10.1002/ppul.26954. Epub 2024 Apr 1. Pediatr Pulmonol. 2024. PMID: 38558542

9

Pathways to ensure universal and affordable access to hepatitis C treatment.

Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M. Douglass CH, et al. BMC Med. 2018 Oct 9;16(1):175. doi: 10.1186/s12916-018-1162-z. BMC Med. 2018. PMID: 30296935 Free PMC article.

10

[No title available]

Hill|Alison M||AM [No authors listed] PMID: 38747095

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

355 results

Search Page